Blackhawk Capital Partners LLC. Increases Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Blackhawk Capital Partners LLC. increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 190.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,176 shares of the medical research company’s stock after acquiring an additional 1,427 shares during the period. Blackhawk Capital Partners LLC.’s holdings in Bio-Rad Laboratories were worth $715,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BIO. Van ECK Associates Corp raised its holdings in Bio-Rad Laboratories by 97.8% in the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after buying an additional 644,530 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Bio-Rad Laboratories by 1.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock valued at $147,583,000 after acquiring an additional 4,260 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock worth $84,571,000 after acquiring an additional 9,584 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Bio-Rad Laboratories during the third quarter valued at approximately $83,681,000. Finally, Mawer Investment Management Ltd. lifted its position in Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BIO shares. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup boosted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Trading Up 0.0 %

NYSE:BIO opened at $280.20 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The stock has a 50-day simple moving average of $331.62 and a two-hundred day simple moving average of $334.10. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.